Source comparison
Sermorelin vs Exogenous Growth Hormone
Direct GH injections bypass the pituitary entirely, delivering a flat dose of recombinant human GH. Studies in GH-deficient adults show 10-20% reductions in total body fat over 6-12 months at therapeutic doses. The effect is more pronounced and faster than any
This comparison does not assign a generated winner or score.
- Direct GH injections bypass the pituitary entirely, delivering a flat dose of recombinant human GH. Studies in GH-deficient adults show 10-20% reductions in total body fat over 6-12 months at therapeutic doses. The effect is more pronounced and faster than any GHRH analog can produce.
- The trade-off is side effects and cost. Exogenous GH at supraphysiological doses causes water retention, joint pain, carpal tunnel syndrome, insulin resistance, and potential long-term cancer risk through elevated IGF-1. Monthly costs for pharmaceutical GH run $800-2,000+. Sermorelin at 300 mcg/day typically costs $150-300 per month.
- Sermorelin's self-limiting feedback loop is its greatest safety advantage. The pituitary responds to sermorelin within its physiological capacity. If IGF-1 rises too high, somatostatin increases and dampens further GH release. Exogenous GH offers no such safeguard. For a complete safety overview, see our peptide safety guide.